Kersten Fischer1, Gerit Theil, Raschid Hoda, Paolo Fornara. 1. Department of Urology and Transplant Center of the Martin Luther University Halle-Wittenberg, Halle/Saale, Germany. kersten.fischer@medizin.uni-halle.de
Abstract
BACKGROUND/AIM: Serum amyloid A (SAA) has been identified as a potential biomarker for renal cell carcinoma. We examined its diagnostic value in patients of different tumor stages. PATIENTS AND METHODS: In our study, 48 patients with localized and 67 patients with advanced renal tumors were included. 24 patients served as a control group. Interleukine 6 (IL-6), C-reactive protein (CRP) and SAA levels were measured preoperatively and at day 5 after nephrectomy. RESULTS: The IL-6, CRP and SAA levels in patients with advanced tumors are significantly higher than those of patients with localized tumors. Advanced tumors were identified with a sensitivity of 78% (SAA), 69% (CRP) and 44% (IL-6). The specificity was 82%, 82% and 94% for SAA, CRP and IL-6, respectively. CONCLUSION: Our results indicate that advanced renal cancers are accompanied by increased levels of acute-phase proteins such as CRP and SAA. SAA is found to be more sensitive than CRP for the indication of advanced renal cancer.
BACKGROUND/AIM: Serum amyloid A (SAA) has been identified as a potential biomarker for renal cell carcinoma. We examined its diagnostic value in patients of different tumor stages. PATIENTS AND METHODS: In our study, 48 patients with localized and 67 patients with advanced renal tumors were included. 24 patients served as a control group. Interleukine 6 (IL-6), C-reactive protein (CRP) and SAA levels were measured preoperatively and at day 5 after nephrectomy. RESULTS: The IL-6, CRP and SAA levels in patients with advanced tumors are significantly higher than those of patients with localized tumors. Advanced tumors were identified with a sensitivity of 78% (SAA), 69% (CRP) and 44% (IL-6). The specificity was 82%, 82% and 94% for SAA, CRP and IL-6, respectively. CONCLUSION: Our results indicate that advanced renal cancers are accompanied by increased levels of acute-phase proteins such as CRP and SAA. SAA is found to be more sensitive than CRP for the indication of advanced renal cancer.
Authors: Ghislaine Scelo; David C Muller; Elio Riboli; Mattias Johansson; Amanda J Cross; Paolo Vineis; Konstantinos K Tsilidis; Paul Brennan; Heiner Boeing; Petra H M Peeters; Roel C H Vermeulen; Kim Overvad; H Bas Bueno-de-Mesquita; Gianluca Severi; Vittorio Perduca; Marina Kvaskoff; Antonia Trichopoulou; Carlo La Vecchia; Anna Karakatsani; Domenico Palli; Sabina Sieri; Salvatore Panico; Elisabete Weiderpass; Torkjel M Sandanger; Therese H Nøst; Antonio Agudo; J Ramón Quirós; Miguel Rodríguez-Barranco; Maria-Dolores Chirlaque; Timothy J Key; Prateek Khanna; Joseph V Bonventre; Venkata S Sabbisetti; Rupal S Bhatt Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Mario Menschikowski; Albert Hagelgans; Susanne Fuessel; Olga A Mareninova; Liana Asatryan; Manfred P Wirth; Gabriele Siegert Journal: Inflamm Res Date: 2013-09-24 Impact factor: 4.575
Authors: A L Pastore; G Palleschi; L Silvestri; D Moschese; S Ricci; V Petrozza; A Carbone; A Di Carlo Journal: Dis Markers Date: 2015-04-02 Impact factor: 3.434